Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Гормональная терапия в климактерии: рекомендации для клинической практики
Гормональная терапия в климактерии: рекомендации для клинической практики
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Обзор. Профилактика и лечение климактерических расстройств, кроме длительной заместительной гормонотерапии, требует проведения комплексных мероприятий, включающих использование пероральных препаратов магния в сочетании с пиридоксином, что нивелирует негативные эффекты гормональной терапии, позитивно влияет на состояние здоровья женщины и сохраняет качество жизни.
Ключевые слова: климакс, заместительная гормонотерапия, магний, пиридоксин.
Key words: menopause, hormone replacement therapy, magnesium, pyridoxine.
Ключевые слова: климакс, заместительная гормонотерапия, магний, пиридоксин.
________________________________________________
Key words: menopause, hormone replacement therapy, magnesium, pyridoxine.
Полный текст
Список литературы
1. Pines A, Sturdee DW, Birkhauser MH. IMS Updated Recommendations on postmenopausal hormone therapy. Climacteric 2007; 10: 195–6.
2. Балан В.Е. Урогенитальные расстройства. В кн.: Руководство по климактерию. Под ред. В.П.Сметник, В.И.Кулакова. М., 2001; с. 194–256.
3. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systemic review. Climacteric 2001; 4: 58–74.
4. Delmas PD, Rizzoli R, Cooper C, Reginster JY. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 2005; 16: 1–5.
5. Rosano GMC, Mercuro G, Vitale C et al. How progestins influence the cardiovascular effect of hormone replacement therapy. Gynecol Endocrinol 2001; 15: 9–17.
6. van de Weijer PH, Mattsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 2007; 56 (3): 231–48.
7. Sitruk-Ware R, Husmann F, Thijssen JHH et al. Role of progestin with partial antiandrogenic effects. Climacteric 2004; 7: 238–54.
8. Lethaby A, Suckling J, Barlow DH et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004; 3: CD000402.
9. Goeretzleher G. The role of progestogens in hormone replacement. Drugs of Today 2001; 37 (Suppl. G): 1–8.
10. Riphagen FE. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric 2000; 3: 199–211.
11. Genazzani AR, Gambacciani M, Simoncini T. Menopause and aging, quality of life and sexuality. IMS Statement following 6th IMS Workshop, Pisa, December 2006. Climacteric 2007; 10: 88–96.
12. Newhouse IJ, Clement DB, Lai C. Med Sci Sport Exerc 1993; 25 (5): 562–71.
13. Сметник В.П., Бутарева Л.Б. Место Магне В6 в коррекции психовегетативных расстройств у женщин с климактерическим синдромом в постменопаузе. Фарматека. 2004; 15 (92): 74–8.
14. Hays J, Ockene J.K, Brunner RL et al. Nengl J Med 2003; 348: 1839–54.
15. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. J Am Med Assoc 2001; 285: 2891–7.
16. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risk, and benefits. Menоpause 2002; 9: 6–15.
2. Балан В.Е. Урогенитальные расстройства. В кн.: Руководство по климактерию. Под ред. В.П.Сметник, В.И.Кулакова. М., 2001; с. 194–256.
3. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systemic review. Climacteric 2001; 4: 58–74.
4. Delmas PD, Rizzoli R, Cooper C, Reginster JY. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 2005; 16: 1–5.
5. Rosano GMC, Mercuro G, Vitale C et al. How progestins influence the cardiovascular effect of hormone replacement therapy. Gynecol Endocrinol 2001; 15: 9–17.
6. van de Weijer PH, Mattsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 2007; 56 (3): 231–48.
7. Sitruk-Ware R, Husmann F, Thijssen JHH et al. Role of progestin with partial antiandrogenic effects. Climacteric 2004; 7: 238–54.
8. Lethaby A, Suckling J, Barlow DH et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004; 3: CD000402.
9. Goeretzleher G. The role of progestogens in hormone replacement. Drugs of Today 2001; 37 (Suppl. G): 1–8.
10. Riphagen FE. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric 2000; 3: 199–211.
11. Genazzani AR, Gambacciani M, Simoncini T. Menopause and aging, quality of life and sexuality. IMS Statement following 6th IMS Workshop, Pisa, December 2006. Climacteric 2007; 10: 88–96.
12. Newhouse IJ, Clement DB, Lai C. Med Sci Sport Exerc 1993; 25 (5): 562–71.
13. Сметник В.П., Бутарева Л.Б. Место Магне В6 в коррекции психовегетативных расстройств у женщин с климактерическим синдромом в постменопаузе. Фарматека. 2004; 15 (92): 74–8.
14. Hays J, Ockene J.K, Brunner RL et al. Nengl J Med 2003; 348: 1839–54.
15. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. J Am Med Assoc 2001; 285: 2891–7.
16. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risk, and benefits. Menоpause 2002; 9: 6–15.
2. Балан В.Е. Урогенитальные расстройства. В кн.: Руководство по климактерию. Под ред. В.П.Сметник, В.И.Кулакова. М., 2001; с. 194–256.
3. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systemic review. Climacteric 2001; 4: 58–74.
4. Delmas PD, Rizzoli R, Cooper C, Reginster JY. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 2005; 16: 1–5.
5. Rosano GMC, Mercuro G, Vitale C et al. How progestins influence the cardiovascular effect of hormone replacement therapy. Gynecol Endocrinol 2001; 15: 9–17.
6. van de Weijer PH, Mattsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 2007; 56 (3): 231–48.
7. Sitruk-Ware R, Husmann F, Thijssen JHH et al. Role of progestin with partial antiandrogenic effects. Climacteric 2004; 7: 238–54.
8. Lethaby A, Suckling J, Barlow DH et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004; 3: CD000402.
9. Goeretzleher G. The role of progestogens in hormone replacement. Drugs of Today 2001; 37 (Suppl. G): 1–8.
10. Riphagen FE. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric 2000; 3: 199–211.
11. Genazzani AR, Gambacciani M, Simoncini T. Menopause and aging, quality of life and sexuality. IMS Statement following 6th IMS Workshop, Pisa, December 2006. Climacteric 2007; 10: 88–96.
12. Newhouse IJ, Clement DB, Lai C. Med Sci Sport Exerc 1993; 25 (5): 562–71.
13. Сметник В.П., Бутарева Л.Б. Место Магне В6 в коррекции психовегетативных расстройств у женщин с климактерическим синдромом в постменопаузе. Фарматека. 2004; 15 (92): 74–8.
14. Hays J, Ockene J.K, Brunner RL et al. Nengl J Med 2003; 348: 1839–54.
15. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. J Am Med Assoc 2001; 285: 2891–7.
16. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risk, and benefits. Menоpause 2002; 9: 6–15.
________________________________________________
2. Балан В.Е. Урогенитальные расстройства. В кн.: Руководство по климактерию. Под ред. В.П.Сметник, В.И.Кулакова. М., 2001; с. 194–256.
3. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systemic review. Climacteric 2001; 4: 58–74.
4. Delmas PD, Rizzoli R, Cooper C, Reginster JY. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 2005; 16: 1–5.
5. Rosano GMC, Mercuro G, Vitale C et al. How progestins influence the cardiovascular effect of hormone replacement therapy. Gynecol Endocrinol 2001; 15: 9–17.
6. van de Weijer PH, Mattsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 2007; 56 (3): 231–48.
7. Sitruk-Ware R, Husmann F, Thijssen JHH et al. Role of progestin with partial antiandrogenic effects. Climacteric 2004; 7: 238–54.
8. Lethaby A, Suckling J, Barlow DH et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004; 3: CD000402.
9. Goeretzleher G. The role of progestogens in hormone replacement. Drugs of Today 2001; 37 (Suppl. G): 1–8.
10. Riphagen FE. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric 2000; 3: 199–211.
11. Genazzani AR, Gambacciani M, Simoncini T. Menopause and aging, quality of life and sexuality. IMS Statement following 6th IMS Workshop, Pisa, December 2006. Climacteric 2007; 10: 88–96.
12. Newhouse IJ, Clement DB, Lai C. Med Sci Sport Exerc 1993; 25 (5): 562–71.
13. Сметник В.П., Бутарева Л.Б. Место Магне В6 в коррекции психовегетативных расстройств у женщин с климактерическим синдромом в постменопаузе. Фарматека. 2004; 15 (92): 74–8.
14. Hays J, Ockene J.K, Brunner RL et al. Nengl J Med 2003; 348: 1839–54.
15. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. J Am Med Assoc 2001; 285: 2891–7.
16. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risk, and benefits. Menоpause 2002; 9: 6–15.
Авторы
Я.З.Зайдиева
ГУЗ Московский областной научно-исследовательский институт акушерства и гинекологии
Key words: menopause, hormone replacement therapy, magnesium, pyridoxine.
ГУЗ Московский областной научно-исследовательский институт акушерства и гинекологии
________________________________________________
Key words: menopause, hormone replacement therapy, magnesium, pyridoxine.
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.